{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=8", "query": { "intervention": "Placebo SC Injection", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 833, "total_pages": 84, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+SC+Injection&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T17:25:11.355Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04881760", "title": "A Study of LY3437943 in Participants Who Have Obesity or Are Overweight", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "LY3437943", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 338, "start_date": "2021-05-20", "completion_date": "2022-11-22", "has_results": true, "last_update_posted_date": "2023-09-13", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 25, "location_summary": "Scottsdale, Arizona • Anaheim, California • Fresno, California + 21 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04881760" }, { "nct_id": "NCT02437162", "title": "A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Axial Spondyloarthritis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Ustekinumab 45 mg", "type": "DRUG" }, { "name": "Ustekinumab 90 mg", "type": "DRUG" }, { "name": "Golimumab 50 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen Research & Development, LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 347, "start_date": "2015-09-03", "completion_date": "2017-09-06", "has_results": true, "last_update_posted_date": "2025-04-29", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 11, "location_summary": "Peoria, Arizona • St. Petersburg, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Peoria", "state": "Arizona" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Eagan", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02437162" }, { "nct_id": "NCT05194124", "title": "Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bardet-Biedl Syndrome", "POMC Deficiency" ], "interventions": [ { "name": "Setmelanotide 2 mg", "type": "DRUG" }, { "name": "Setmelanotide 2.5 mg", "type": "DRUG" }, { "name": "Setmelanotide 3 mg", "type": "DRUG" }, { "name": "Setmelanotide 20 mg", "type": "DRUG" }, { "name": "Setmelanotide 25 mg", "type": "DRUG" }, { "name": "Setmelanotide 30 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 19, "start_date": "2021-12-21", "completion_date": "2023-10-19", "has_results": true, "last_update_posted_date": "2024-11-26", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Marshfield, Wisconsin", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Marshfield", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05194124" }, { "nct_id": "NCT00048542", "title": "Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Juvenile Idiopathic" ], "interventions": [ { "name": "Double-Blind Adalimumab/Placebo + MTX", "type": "BIOLOGICAL" }, { "name": "Double-Blind Adalimumab/Placebo", "type": "BIOLOGICAL" }, { "name": "OLE BSA Adalimumab +/- MTX", "type": "DRUG" }, { "name": "OLE FD Adalimumab +/- MTX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 171, "start_date": "2002-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-08-22", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048542" }, { "nct_id": "NCT01709513", "title": "Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypercholesterolemia" ], "interventions": [ { "name": "Atorvastatin", "type": "DRUG" }, { "name": "Ezetimibe", "type": "DRUG" }, { "name": "Alirocumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 314, "start_date": "2012-09-30", "completion_date": "2017-05-31", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 41, "location_summary": "Anaheim, California • Beverly Hills, California • Mission Viejo, California + 38 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Mission Viejo", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Northridge", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01709513" }, { "nct_id": "NCT02896192", "title": "Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pro-opiomelanocortin (POMC) Deficiency Obesity" ], "interventions": [ { "name": "Setmelanotide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhythm Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 15, "start_date": "2017-02-14", "completion_date": "2020-05-25", "has_results": true, "last_update_posted_date": "2023-09-21", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT02896192" }, { "nct_id": "NCT00079937", "title": "Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Omalizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Fluticasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "11 Years", "sex": "ALL", "summary": "6 Years to 11 Years" }, "enrollment_count": 628, "start_date": "2004-04", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2012-04-11", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 56, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Huntington Beach, California + 48 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079937" }, { "nct_id": "NCT05281328", "title": "A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Polycystic Liver Disease" ], "interventions": [ { "name": "CAM2029", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Camurus AB", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 71, "start_date": "2022-06-28", "completion_date": "2027-08", "has_results": true, "last_update_posted_date": "2026-06-01", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 6, "location_summary": "Rochester, Minnesota • New York, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281328" }, { "nct_id": "NCT04987307", "title": "Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ulcerative Colitis" ], "interventions": [ { "name": "Efavaleukin alfa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 221, "start_date": "2022-01-31", "completion_date": "2024-10-22", "has_results": true, "last_update_posted_date": "2026-01-13", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 63, "location_summary": "Dothan, Alabama • Homewood, Alabama • Mesa, Arizona + 57 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Homewood", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04987307" }, { "nct_id": "NCT06637371", "title": "A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "AMG 691", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 21, "start_date": "2024-10-16", "completion_date": "2027-04-10", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-29T17:25:11.355Z", "location_count": 15, "location_summary": "Lake Forest, California • Aventura, Florida • Palmetto Bay, Florida + 12 more", "locations": [ { "city": "Lake Forest", "state": "California" }, { "city": "Aventura", "state": "Florida" }, { "city": "Palmetto Bay", "state": "Florida" }, { "city": "Columbus", "state": "Georgia" }, { "city": "White Marsh", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06637371" } ] }